NICE - Endorsed Technology Appraisals 2025/2026

Topics:

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

https://www.health-ni.gov.uk/topics/nice-technology-appraisalsTechnology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2025/2026

The following technology appraisals have been endorsed during 2025/26. Information on technology appraisals endorsed in previous years can be found on the homepage.

November 2025

TA1110 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer Note this guidance updates and replaces NICE Technology Appraisal TA721, endorsed by the DoH in September 2021.

https://www.nice.org.uk/guidance/ta1110

TA1109 - Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

TA1108 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

TA1107 - Delgocitinib for treating moderate to severe chronic hand eczema

TA1106 - Cabotegravir for preventing HIV-1 in adults and young people

TA1103 - Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

TA1101 - Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

October 2025

TA1099 - Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

TA1098 - Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

TA1097 - Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

September 2025

TA1096 - Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

TA1095 - Guselkumab for previously treated moderately to severely active Crohn's disease

TA1094 - Guselkumab for treating moderately to severely active ulcerative colitis

TA1093 - Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over

TA1092 - Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer

TA1091 - Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments

TA1090 - Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

TA1088 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

TA1087- Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen

August 2025

TA1086 - Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence

TA1085 - Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

TA1081 - Zanubrutinib for treating relapsed or refractory mantle cell lymphoma

TA1080 - Mirikizumab for preciously treated moderately to severely active Crohn's disease

TA1079 - Fruquintinib for previously treated metastatic colectoral cancer

July 2025

TA1077 - Nemolizub for treating moderate to severe atopic dermatitis in people in 12 years and over

TA1075 - Dapagliflozin for treating chronic kidney disease ‘Note this guidance updates and replaces NICE Technology Appraisal TA775, endorsed by the DoH in March 2022’.

TA1074 - Sparsentan for treating primary IgA nephropathy

TA1073 - Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesCE

TA1071 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerNote this guidance updates and replaces NICE Technology Appraisal TA823, endorsed by the DoH in October 2022’